ESPLINE® SARS-CoV-2
ESPLINE SARS-CoV-2 is for in vitro diagnostic (IVD) use with immunochromatographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab fluid and is intended for use as an aid in the diagnosis of SARS-CoV-2 infection.
ESPLINE SARS-CoV-2 is a cassette-style assay using a simple procedure without any special instruments. SARS-CoV-2 can be detected within 30 minutes.
Product number 231906
Click here to navigate
- Details
- Conditions of sale
- Documentation
- FAQ
- Insights
- Related products
- Product inquiry
-
Details
About SARS-CoV-2
The 2019 novel coronavirus infection disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2 In December 2019, the Health Commission of the City of Wuhan, Hubei Province, China, reported multiple pneumonia patients with unknown cause. On January 7th 2020, the World Health Organization (WHO) announced that the National Health Commission of China identified a new type of coronavirus, SARS-CoV-2.3 The WHO declared a COVID-19 pandemic on March 11th 2020 due to the worldwide spread of novel coronavirus infection.4
The detection of viruses in the body of the patient is the most effective way of confirming SARS-CoV-2 infection. In most countries including Japan, the diagnosis of SARS-CoV-2 infection is based on the molecular detection of the SARS-CoV-2 genes. Though nucleic acid-based test can detect SARS-CoV-2 gene with high sensitivity, it is affected by the need of special equipment and the duration of reaction time.
References
- Wu F, et al. A new coronavirus associated with human respiratory disease in China Nature, 579: 265-269, 2020.
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-Nat Microbiol, 5: 536-544, 2020.
- WHO website ”Rolling updates on coronavirus disease(COVID-19)” (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-…) Medical Research and Development.
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 (https://www.who.int/dg/speeches/detail/who-director-general-sopening-re…)
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
Multimedia
Watch product videos
Get a (free!) eServices account and benefit from full access to all our online resources.
-
Insights
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Oct 19, 2020
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Aug 26, 2020
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry